Taselisib

Search with Google Search with Bing

Information
Drug Name
Taselisib
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
head and neck squamous cell carcinoma PIK3CA AMPLIFICATION
( ENST00000263967.4, ENST00000497599.5 ) PIK3CA AMPLIFICATION
( ENST00000263967.4 ) 		D Predictive Supports Sensitivity/Response Somatic 1 26589432 Detail
head and neck squamous cell carcinoma PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 26589432 Detail
head and neck squamous cell carcinoma PTEN MUTATION PTEN MUTATION D Predictive Supports Resistance Somatic 3 26589432 Detail
head and neck squamous cell carcinoma PIK3CA MUTATION PIK3CA MUTATION D Predictive Supports Sensitivity/Response Somatic 3 26589432 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
The HNSCC cell line LB771 with PIK3CA amplificatio... PIK3CA PIK3CA AMPLIFICATION
( ENST00000263967.4, ENST00000497599.5 ) PIK3CA AMPLIFICATION
( ENST00000263967.4 ) 		Sensitivity true CIViC Evidence detail
The Cal-33 HNSCC cell line with H1047R mutation wa... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
In a panel of 26 HNSCC cell lines tested for sensi... PTEN PTEN MUTATION PTEN MUTATION Resitance or Non-Reponse true CIViC Evidence detail
A panel of 26 HNSCC cell lines was tested for effi... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02390427 Active, not recruiting Phase 1 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer April 20, 2015 May 2024
NCT02465060 Active, not recruiting Phase 2 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) August 17, 2015 December 31, 2025
NCT04439175 Active, not recruiting Phase 2 Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) February 25, 2016 March 7, 2025
NCT02154490 Completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer July 8, 2014 April 15, 2022
NCT02273973 Completed Phase 2 A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) November 12, 2014 March 13, 2017
NCT02785913 Completed Phase 2 Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches November 2014 November 2019
NCT02340221 Terminated Phase 3 A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy April 9, 2015 June 29, 2021
NCT02457910 Terminated Phase 1/Phase 2 Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer June 2015 August 8, 2022